Enavate Sciences GP, LLC
NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$279.8M2026 Q3
Positions8
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.100.0%
Top Holdings
ZBIO
Zenas BioPharma
28.1%
IMNM
Immunome
27.8%
BRVE
Braveheart Bio
26.5%
SION
Sionna Therapeutics
4.7%
UPB
Upstream Bio
4.6%
BBOT
BridgeBio Oncology Therapeutics
3.8%
CMPX
Compass Therapeutics
2.9%
CAMP
Camp4 Therapeutics
1.5%
Reduced / Exited
2 reduced · 0 sold out
ZBIO
Zenas Biopharma
28.1%
-25.5%
CAMP
CAMP4 Therapeutics
1.5%
-27.0%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.